Cost Action CA1703 started yesterday with a kick off meeting in Brussels.
Management committee members representing the 25 countries that currently take part in this network agreed on the first steps of the action, including assigning the role of Chair to Dr. Virginia Arechavala-Gomeza.
This COST Action will run until October 2022 and aims to overcome delivery problems of antisense RNA therapeutics.
https://www.cost.eu/actions/CA17103#tabs|Name:overview
